James Meigs, MD, MPH

Co-Director of the MGH Clinical Research Program’s Clinical Effectiveness Research Group James Meigs
Professor of Medicine at Harvard Medical School
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Meigs is Professor of Medicine at Harvard Medical School, Physician, Division of General Internal Medicine, Massachusetts General Hospital and Co-Director of the MGH Clinical Research Program’s Clinical Effectiveness Research Group.

For over 25 years Dr. Meigs has been a practicing primary care general internist in the MGH Internal Medicine Associates.

Dr. Meigs' research interest for over 20 years has been the cause and prevention of type 2 diabetes and cardiovascular disease. He has authored more than 400 peer-reviewed scientific papers (Thomson Reuters Highly Cited Researcher 2014), supported by multiple NIH and foundation research grants, currently including 2R01 DK078616: Common Genetic Variation and Diabetes Quantitative Traits (PI), U01 DK085526: Multiethnic Study of Type 2 Diabetes Genetics (Co-PI) and K24 DK080140: Epidemiology of Precursors to Type 2 Diabetes (PI). He is a senior scientific leader of several large international type 2 diabetes-related genetic consortia, including MAGIC (Meta Analysis of Glucose and Insulin Consortium), AAGILE (African American Glucose and Insulin genetic Epidemiology) and CHARGE (Cohorts for Heart and Aging Genetic Epidemiology).

Dr. Meigs has mentored over 50 junior clinical research investigators, supported in part by the NIDDK K24 award. In 2009, he was awarded the American Diabetes Association’s Kelly West Award for Outstanding Achievement in Diabetes Epidemiology.

Publications

  • Walford, G. A., Green, T., Neale, B., Isakova, T., Rotter, J. I., Grant, S. F., Fox, C. S., Pankow, J. S., Wilson, J. G., Meigs, J., Siscovick, D. S., Bowden, D. W., Daly, M. J. & Florez, J. C. (2012). Common genetic variants differentially influence the transition from clinically defined states of fasting glucose metabolism. Diabetologia, 55, 331-9. [Online version]
  • Rienstra, M., Sun, J. X., Lubitz, S. A., Frankel, D. S., Vasan, R. S., Levy, D., Magnani, J. W., Sullivan, L. M., Meigs, J., Ellinor, P. T. & Benjamin, E. J. (2012). Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J, 163, 119-124 e1. [Online version]
  • Liu, E., McKeown, N. M., Pittas, A. G., Meigs, J., Economos, C. D., Booth, S. L. & Jacques, P. F. (2012). Predicted 25-hydroxyvitamin D score and change in fasting plasma glucose in the Framingham offspring study. Eur J Clin Nutr, 66, 139-41. [Online version]
  • Thacker, E. L., Psaty, B. M., McKnight, B., Heckbert, S. R., Longstreth, W. T., Mukamal, K. J., Meigs, J., de Boer, I. H., Boyko, E. J., Carnethon, M. R., Kizer, J. R., Tracy, R. P., Smith, N. L. & Siscovick, D. S. (2011). Fasting and post-glucose load measures of insulin resistance and risk of ischemic stroke in older adults. Stroke, 42, 3347-51. [Online version]
  • Upadhyay, A., Larson, M. G., Guo, C. Y., Vasan, R. S., Lipinska, I., O'Donnell, C. J., Kathiresan, S., Meigs, J., Keaney, J. F., Rong, J., Benjamin, E. J. & Fox, C. S. (2011). Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant, 26, 920-6. [Online version]